Name: Lirafit Pen
SKU: 23972
Availability: InStock

📋 Product Overview Table

🌐 Specification	🧾 Details
💊 Active Ingredient	Liraglutide
🧪 Strength	6 mg/mL
🏭 Manufacturer	Glenmark Pharmaceuticals Ltd
🤝 Brand Distributor	Novo Nordisk India
💉 Form	Subcutaneous Injection (pre-filled pen)
📦 Packaging	3 mL in 1 pre-filled pen
🩺 Indication	Type 2 Diabetes Mellitus; Chronic Weight Management (off-label)
🇺🇸 US Brand	Victoza (Liraglutide)
⏱️ Delivery Time	6 to 15 days

🧬 Introduction – What Is Lirafit Pen (Liraglutide)?

Lirafit Pen delivers Liraglutide, a GLP-1 receptor agonist designed to manage Type 2 diabetes mellitus and support weight loss in obese or overweight adults. Manufactured by Glenmark Pharmaceuticals and distributed by Novo Nordisk India, this 6 mg/mL solution comes in a convenient pre-filled pen, allowing for daily subcutaneous injections with precise dose control.

Liraglutide reduces blood glucose levels, delays gastric emptying, and promotes satiety. Its once-daily administration helps improve metabolic health, especially in individuals with cardiovascular risk or insulin resistance. Lirafit is considered a more affordable and accessible version of the internationally marketed Victoza®.

🎥 Video Overview – How Liraglutide (Lirafit) Works

📺 “GLP-1 Therapy with Liraglutide: Diabetes & Weight Management Explained”

🎬 Video Placeholder – Visual guide to mechanism, injection technique, and benefits.

Tip: Inject subcutaneously in the thigh, upper arm, or abdomen. Rotate injection sites regularly.

🩺 Indications & Therapeutic Benefits

Blood glucose control in adults with Type 2 diabetes
Weight reduction in patients with metabolic syndrome (off-label)
Delays need for insulin in early-stage diabetics
Cardiovascular event reduction in high-risk populations

💡 Dosage & Administration

🕒 Phase	💊 Dose Recommendation
Initial Titration	0.6 mg once daily for one week
Therapeutic Dose	Increase to 1.2 mg daily after 7 days
Maximum Dose	Up to 1.8 mg daily, depending on glycemic response
Route	Subcutaneous injection only

Administer at the same time each day. Do not mix with insulin or other drugs in the same injection.

⚠️ Side Effects & Warnings

💥 Common Reactions	❗ Serious Adverse Events
Nausea, diarrhea, fatigue	Pancreatitis (rare but severe)
Appetite loss, dyspepsia	Hypoglycemia (when used with sulfonylureas)
Injection site reactions	Thyroid tumors (seen in rodent studies)

Avoid use in: patients with history of medullary thyroid carcinoma or MEN 2 syndrome.

🧃 Storage & Handling

Store refrigerated between 2°C and 8°C
After first use, store at room temperature (below 30°C) for up to 30 days
Do not freeze. Keep away from light and heat

🌍 Global Ordering & Availability Guide

🌎 Region	📦 Import Policy	📋 Prescription Requirement
🇺🇸 USA	FDA personal import allowed (Rx)	Yes
🇬🇧 UK	Permitted with prescription (MHRA)	Yes
🇦🇺 Australia	Personal import scheme (TGA)	Yes

🔗 Related Products (Internal Links)

💊 Medicine	🏭 Manufacturer	📖 Description
Rybelsus 14mg	Novo Nordisk India	Oral GLP-1 therapy for blood sugar management
Ozempic 1mg	Novo Nordisk	Weekly injectable Semaglutide for Type 2 diabetes
Trulicity 1.5mg	Eli Lilly	Long-acting GLP-1 injection with CV risk benefits
Victoza 6mg/ml	Novo Nordisk	Global brand of Liraglutide in pre-filled pen
Jardiance 25mg	Boehringer Ingelheim	SGLT2 inhibitor for glucose control and heart failure risk

📚 References & Trusted Sources

FDA Victoza Prescribing Info
Novo Nordisk Global – Liraglutide
NHS – GLP-1 Agonist Info
PubMed – Liraglutide Studies

🩺 Expert Review – Dr. Neeraj Mehta, MD (Diabetes & Obesity Specialist)

“Lirafit 6mg/mL is an accessible and effective Liraglutide formulation for Indian and global patients seeking needle-based GLP-1 therapy. It’s comparable to Victoza and supports weight and sugar control simultaneously.”

⚠️ Disclaimer

This article is for educational purposes only. Lirafit (Liraglutide 6mg/mL) is a prescription medication. Use only under medical supervision and according to local regulations.